WHY GLIOBLASTOMA

Glioblastoma (GBM) remains one of the most difficult solid tumors to treat. Current therapies are limited by invasive growth, tumor heterogeneity, immune suppression, and recurrence after standard treatment.

Galt’s initial focus on glioblastoma reflects the need for therapeutic platforms that can address multiple biological barriers at once. The company is developing preclinical strategies aimed at improving tumor targeting, functional control, and engineered-cell performance in hostile solid-tumor environments.

Heterogeneous targets
Glioblastoma tumors often contain mixed cell populations with variable antigen expression.

Suppressive microenvironment
The tumor environment can limit immune-cell persistence, activation, and killing function.

Need for programmable control
Future therapies may require tunable systems rather than fixed, single-function cell products.

Technology Areas

VHH and Nanobody Discovery

Galt is evaluating compact tumor-binding domains for use in CAR-T design, AAV targeting, and other engineered therapeutic systems.

Targeted Gene Integration

The company explores site-specific integration strategies designed to improve genetic control, reproducibility, and construct architecture.

RNA-Guided Regulation

Galt is developing concepts involving programmable RNA-guided systems for multiplexed control of cellular pathways relevant to solid-tumor therapy.

Inducible Expression Systems

The platform uses inducible-control concepts to regulate selected therapeutic components and reduce reliance on permanently active expression.

Vector and Payload Engineering

Galt evaluates lentiviral, AAV, minicircle, and other delivery approaches with attention to payload size, manufacturability, and functional feasibility.

How Galt Builds Therapeutic Assets

Galt is structured to develop early-stage biotechnology assets without immediately relying on a large internal laboratory footprint. The company advances programs through a focused operating model built around design, validation, collaboration, and intellectual-property development.

Internal Platform Design

Galt develops therapeutic architectures, construct designs, target strategies, and experimental plans internally.

Specialized CRO Execution

The company uses external vendors for defined technical work such as VHH discovery, protein production, cell screening, vector design, and assay support.

Academic Research Partnerships

Galt seeks sponsored research collaborations with academic laboratories that have deep expertise in cell therapy, immuno-engineering, cancer biology, and translational science.

IP and Licensing Strategy

We aim to convert early scientific work into defensible intellectual property, licensing opportunities, and future therapeutic development programs.

How Galt Builds Therapeutic Assets

Program Area	Focus	Stage
Glioblastoma CAR-T Platform	Programmable immune-cell therapy for treatment-resistant glioblastoma	Preclinical design
VHH Tumor Targeting	Nanobody/VHH discovery for solid-tumor recognition and modular CAR design	Discovery
RNA-Guided Cell Regulation	Multiplexed RNA-control systems for engineered immune cells	Platform development
Targeted Integration	Site-specific engineering strategies for stable therapeutic payload insertion	Platform development
Vector and Payload Engineering	Feasibility testing for large, modular therapeutic constructs	Design and validation

Our Thesis

Solid-tumor cell therapy will require a new generation of programmable therapeutic systems. Single-antigen targeting alone is unlikely to solve the combined problems of antigen escape, off-tumor toxicity, tumor heterogeneity, immune suppression, and poor persistence.

Galt’s thesis is that the next major advances in solid-tumor cell therapy will come from engineered cells that can combine:

• multi-target tumor recognition;
• regulated gene expression;
• programmable RNA-guided control;
• resistance to suppressive tumor environments;
• precise genetic integration;
• modular, manufacturable therapeutic design.